Celadon Pharmaceuticals PLC Result of AGM (4485E)
2023年6月30日 - 1:30AM
RNSを含む英国規制内ニュース (英語)
TIDMCEL
RNS Number : 4485E
Celadon Pharmaceuticals PLC
29 June 2023
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Result of Annual General Meeting
London, UK, 29 June 2023 : Celadon Pharmaceuticals Plc (AIM:
CEL), a UK-based pharmaceutical company focused on the research,
cultivation, manufacturing and sale of breakthrough cannabis-based
medicines, announces that at its Annual General Meeting held today,
all resolutions were duly passed.
Full details of the poll results will shortly be set out on the
Company's website .
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Jonathan Turner
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Bobbie Hilliam / Andrew Potts / Patrick
Dolaghan +44 (0)20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums
/
Ibrahim Khalil +44 (0)20 7250 1446
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and sale of
breakthrough cannabis-based medicines. Its primary focus is on
improving quality of life for chronic pain sufferers, as well as
exploring the potential of cannabis-based medicines for other
conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP
approved and comprises indoor hydroponic cultivation, proprietary
GMP extraction and manufacturing and an analytical and R&D
laboratory. Celadon's Home Office licence allows for the commercial
supply of its GMP pharmaceutical cannabis product. The Company's
subsidiary, LVL, owns a MHRA conditionally-approved clinical trial
using cannabis based medicinal products to treat chronic pain in
the UK. Celadon also has a minority interest in early-stage
biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum
Disorder.
For further information please visit our website
www.celadonpharma.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGNKCBDABKDPAB
(END) Dow Jones Newswires
June 29, 2023 12:30 ET (16:30 GMT)
Celadon Pharmaceuticals (LSE:CEL)
過去 株価チャート
から 4 2024 まで 5 2024
Celadon Pharmaceuticals (LSE:CEL)
過去 株価チャート
から 5 2023 まで 5 2024